EL7.AI
StocksMedium•19 November 2026•
1 min read

German Court Overturns Injunction Against Merck, Resuming Keytruda SC Launch

Key Facts

1The Higher Regional Court in Germany overturned a preliminary injunction that had prevented Merck from distributing Keytruda SC.
2Halozyme expressed disappointment over the ruling which allows Merck to resume the launch of the product in the German market.

The Higher Regional Court in Germany overturned a preliminary injunction that had prevented Merck from distributing and offering its Keytruda SC formulation. PR Newswire reported that the ruling reverses a December 2025 decision, allowing the company to resume its product launch in the German market.

Halozyme expressed disappointment over the ruling, which impacts its leverage in the ongoing patent dispute. Regarding market performance, Merck shares closed at $137.78 on November 18, 2026, while Halozyme shares closed at $95.8 on the same date.

Open on chart